Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tolfenamic acid is a non-steroidal anti-inflammatory drug (NSAID) of the fenamate class (anthranilic acid derivatives), primarily used for its analgesic and anti-inflammatory properties. It is indicated for the treatment of migraine headaches and other conditions associated with pain and inflammation. The drug acts mainly by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), leading to reduced synthesis of prostaglandins, which are mediators of inflammation, pain, and fever. Tolfenamic acid also inhibits leukotriene synthesis and has been shown to partially inhibit leukotriene B4 chemotaxis in human polymorphonuclear leukocytes. Additionally, research suggests it may have anti-cancer activity by altering gene expression related to apoptosis, growth arrest, angiogenesis, and metastasis[1][2][3][6][8]. It was originally discovered by Medica Pharmaceutical Company in Finland[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tolfenamic acid.